Common side effects in clinical trials included headache (19% of patients under mepolizumab treatment versus 18% under placebo), reactions at the site of injection (8% versus 3%), infections of the [[urinary tract]] (3% versus 2%) and the [[lower respiratory tract]], [[eczema]] and muscle spasms (both 3% versus <1%).<ref name="SPC">{{cite web|publisher=European Medicines Agency| title=Nucala Summary of Product Characteristics |url=http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003860/WC500198037.pdf|date=December 2015}}</ref><ref name="Drugs.com">{{drugs.com|pro|nucala}} for Nucala.</ref>

 

